Effect of Eicosapentaenoic Acid Ethyl Ester on Albuminuria in Streptozotocin-Induced Diabetic Rats.

Abstract

SummaryWistar rats (4-week-old) were administered with streptozo tocin (45mg/kg) through tail veins. After 3 months, diabetic rats were divided into 2 groups. One group (EPA group, n=16) was fed a lipid-free diet (90%, w/w) plus lard (8%) and 90% pure eicosapentaenoic acid ethyl ester (2%) for 6 months. The other group (control group, n= 16) was fed in the same way except that eicosapentaenoic acid ethyl ester was replaced by safflower oil. Twenty-four-hour urine was collected just before starting the experimental diets and during the 6-month experimen tal period at monthly intervals. There were no differences in food intake and body weight between the two groups throughout the experiment. The mean microalbuminuria of the EPA group became significantly lower than that of the control group after 4 months on the diets through the end of the study (6 months). The mean microalbuminuria levels at the end of the study were 1.38mg/day in the EPA group (n=9) and 5.19mg/day in the control group (n=6) (p<0.01). Eicosapentaenoic acid administra tion might retard the progression of diabetic nephropathy by reducing microalbuminuria.

Inducible NOS inhibition, eicosapentaenoic acid supplementation, and angiotensin II–induced renal damage

“…The capacity of n-3 PUFAs to ameliorate renal damage is not restricted to our transgenic rat model. EPA was reported to retard the progression of diabetic nephropathy in streptozotocin-treated rats [42] and to prevent the development of glomerulosclerosis in a 5/6 renal ablation model [43]. Moreover, n-3 PUFAs delayed proteinuria, lowered blood pressure and improved the antioxidant status in spontaneously hypertensive rats [44,45].…”

Omega-3 fatty acid rich diet prevents diabetic renal disease

“…Clinical studies have shown that treatment with n-3 PUFA lowers the risk of development of albuminuria in young type 1 diabetic patients (35) and slows the progression of albuminuria in older patients with type 2 diabetes (44). Eicosapentaenoic acid ethyl ester reduces albuminuria in STZ-induced Sprague-Dawley rats (3,19). How-…”

“…Epidemiological studies suggest that n-3 PUFA slow the progression of renal dysfunction, e.g., prevent the decline in creatinine clearance in healthy older people (28), lessen the risk of albuminuria in young type 1 diabetic patients (35), and slow the progression of albuminuria in older patients with type 2 diabetes (44). Furthermore, dietary PUFA have been shown to have renoprotective effects in experimental models of diabetes (3,19). However, the mechanisms by which n-3 PUFA exert this renoprotection are unclear.…”

Promotion, prediction and prevention of progression of nephropathy in Type 1 diabetes mellitus

“…[164][165][166][167] The discrepancies could relate to differences in the fish oil preparations or the type of patients. It is also possible that some of the effects observed in short-term studies are transient, as a study from our clinic 164 using almost the same oil as in our study for 8 weeks in a cross-over study in Type 1 DM patients with micro-and macroalbuminuria did find a reduction in blood pressure and transcapillary escape rate of albumin and an improvement in the lipid profile 164 in contrast to our long-term study.…”